Cingulate Inc. Earnings Per Share (Diluted)
Cingulate Inc. (CING) reported Earnings Per Share (Diluted) of -$0.45 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-13
- Cingulate Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.45.
- Cingulate Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.95.
- Cingulate Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.93.
- Cingulate Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$1.35.
- Cingulate Inc. earnings per share, diluted for fiscal 2025 was -$4.44.
- Cingulate Inc. earnings per share, diluted for fiscal 2024 was -$10.86.
- Cingulate Inc. earnings per share, diluted for fiscal 2023 was -$311.99.
- Cingulate Inc. earnings per share, diluted for fiscal 2022 was -$29.35.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 9 month as first filed | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.45 10-Q · filed 2026-08-13 | -$1.32 10-Q · filed 2026-08-13 | -$2.17 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$3.28 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2026-03-31 | -$0.95 10-Q · filed 2026-05-14 | -$1.89 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$3.13 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$4.24 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-12-31 | -$0.93 derived: net income ÷ weighted average shares · filed 2026-03-18 | -$2.24 derived: net income ÷ weighted average shares · filed 2026-03-18 | -$3.37 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$4.44 10-K · filed 2026-03-18 | ||||
| 2025-09-30 | -$1.35 10-Q · filed 2025-11-13 | -$2.51 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$3.60 10-Q · filed 2025-11-13 | -$5.35 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-06-30 | -$1.14 10-Q · filed 2026-08-13 | -$1.09 10-Q · filed 2025-08-19 | -$2.20 10-Q · filed 2026-08-13 | -$2.14 10-Q · filed 2025-08-19 | -$3.99 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$5.86 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||
| 2025-03-31 | -$1.06 10-Q · filed 2026-05-14 | -$1.04 10-Q · filed 2025-05-08 | -$2.91 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$4.90 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$7.51 derived: net income ÷ weighted average shares · filed 2026-08-13 | |||
| 2024-12-31 | -$1.89 derived: net income ÷ weighted average shares · filed 2026-03-18 | -$4.10 derived: net income ÷ weighted average shares · filed 2026-03-18 | -$7.22 derived: net income ÷ weighted average shares · filed 2026-03-18 | -$10.86 10-K · filed 2026-03-18 | -$10.20 10-K · filed 2025-03-27 | |||
| 2024-09-30 | -$2.34 10-Q · filed 2025-11-13 | -$1.83 10-Q · filed 2024-11-07 | -$6.25 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$11.03 10-Q · filed 2025-11-13 | -$10.06 10-Q · filed 2024-11-07 | -$23.91 derived: net income ÷ weighted average shares · filed 2025-11-13 | ||
| 2024-06-30 | -$5.47 10-Q · filed 2025-08-19 | -$12.28 10-Q · filed 2025-08-19 | -$35.14 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$63.51 derived: net income ÷ weighted average shares · filed 2025-11-13 | ||||
| 2024-03-31 | -$7.21 10-Q · filed 2025-05-08 | -$0.60 10-Q · filed 2024-05-08 | -$37.02 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$77.16 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$56.53 derived: net income ÷ weighted average shares · filed 2025-11-13 | |||
| 2023-12-31 | -$56.32 derived: net income ÷ weighted average shares · filed 2025-03-27 | -$125.68 derived: net income ÷ weighted average shares · filed 2025-03-27 | -$49.65 derived: net income ÷ weighted average shares · filed 2025-03-27 | -$311.99 10-K · filed 2025-03-27 | -$26.00 10-K · filed 2024-04-01 | |||
| 2023-09-30 | -$72.60 10-Q · filed 2024-11-07 | -$0.30 10-Q · filed 2023-11-13 | -$23.83 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$278.84 10-Q · filed 2024-11-07 | -$1.16 10-Q · filed 2023-11-13 | $2.84 derived: net income ÷ weighted average shares · filed 2024-11-07 | ||
| 2023-06-30 | -$6.79 10-Q · filed 2024-08-13 | -$0.57 10-Q · filed 2023-08-14 | -$11.08 10-Q · filed 2024-08-13 | -$0.92 10-Q · filed 2023-08-14 | $1.52 derived: net income ÷ weighted average shares · filed 2024-11-07 | $4.13 derived: net income ÷ weighted average shares · filed 2024-11-07 | ||
| 2023-03-31 | -$7.08 10-Q · filed 2024-05-08 | $0.56 derived: net income ÷ weighted average shares · filed 2024-11-07 | $1.93 derived: net income ÷ weighted average shares · filed 2024-11-07 | $8.00 derived: net income ÷ weighted average shares · filed 2024-11-07 | ||||
| 2022-12-31 | $0.15 derived: net income ÷ weighted average shares · filed 2024-04-01 | $0.85 derived: net income ÷ weighted average shares · filed 2024-04-01 | $4.27 derived: net income ÷ weighted average shares · filed 2024-04-01 | -$29.35 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | -$0.36 10-Q · filed 2023-11-13 | -$0.71 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$1.16 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | -$0.36 10-Q · filed 2023-08-14 | -$0.80 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |